NCT02024386View on ClinicalTrials.gov

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Hypertension, PulmonaryAltitude Sickness
Interventions
DRUG

Riociguat

After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.

Trial Locations (1)

27710

Duke Center for Hyperbaric Medicine and Environmental Physiology, Trent Drive, Building CR2, Room 0584, Box 3823,, Durham

All Listed Sponsors
lead

Richard Moon

OTHER

NCT02024386 - Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude | Biotech Hunter | Biotech Hunter